Second trimester screening tests are a combination of blood tests and an ultrasound offered between 15 and 22 weeks of pregnancy to detect Down syndrome, trisomy 18, and neural tube defects. These tests do not diagnose a condition—they measure your risk of carrying a baby with one of these conditions, and a positive result only means you need further evaluation and counseling before deciding whether to pursue diagnostic testing.
You do not have to have these tests. All pregnant people, regardless of age, should be offered screening and the chance to discuss whether it fits your goals, but the decision is yours. Understanding what the tests measure, how accurate they are, what a positive result means, and what comes next will help you decide whether to proceed and how to interpret your results.
Table of Contents
- What Second Trimester Screening Tests Include
- When Second Trimester Screening Happens
- What the Quad Screen Blood Test Measures
- The Anatomy Ultrasound at 18-22 Weeks
- Understanding Detection Rates and False Positives
- What a Positive Result Means (and Does Not Mean)
- Screening Versus Diagnosis: What Comes Next
- Why Accurate Gestational Age Matters More Than You'd Think
- Screening Is Offered to All Pregnant People, Regardless of Age
- Questions to Ask Your Care Provider Before and After Screening
- Frequently Asked Questions
What Second Trimester Screening Tests Include
[Quad screen blood test 81-83% detection rate, F2] [Second trimester combines blood tests and ultrasound, F1] Second trimester screening combines two separate assessments. The first is a blood test, usually called the quad screen, which measures four markers in your blood: alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), unconjugated estriol (uE3), and inhibin-A.
These four substances are naturally present in your blood during pregnancy, and their levels vary in predictable ways as your pregnancy progresses. The blood test alone detects 81–83% of Down syndrome cases and can also assess risk for trisomy 18 and neural tube defects. most practices perform this test between 15 and 22 weeks of pregnancy, though accuracy improves with proper dating—a point we'll return to because it matters significantly.
The second part is a structural ultrasound, usually performed at 18 to 22 weeks of pregnancy. This ultrasound is recommended for all pregnant patients and serves multiple purposes beyond screening: it checks fetal heart rate, estimates amniotic fluid volume, looks for structural abnormalities, and allows the sonographer to measure bones and other features to confirm your due date.
The ultrasound findings can refine your individual risk estimate from the blood test. Together, the blood test and ultrasound create a more complete picture than either test alone. Neither one by itself tells you whether your baby has a chromosomal condition. A negative result (low risk) is reassuring but not a guarantee. A positive result (high risk) requires conversation with a genetic counselor and, often, a choice between more information through diagnostic testing or proceeding with pregnancy based on screening alone.
This package of tests is offered to all pregnant patients at no cost in most insurance plans and many prenatal clinics offer it regardless of ability to pay. Your provider should give you educational materials and the option to ask questions before testing.
When Second Trimester Screening Happens
[Timing 15-22 weeks, F1] [Dating accuracy critical, marker levels vary by week, F7] Timing matters because the markers your screening test measures change predictably each week of pregnancy. If your gestational age is wrong—off by even two weeks—your results can be misinterpreted. A level that is normal for 16 weeks might look high for 14 weeks or low for 18 weeks, and an incorrect age can shift you from low risk to high risk or vice versa.
Your gestational age is calculated first from your last menstrual period. Most providers then confirm this date with an early ultrasound, typically between 8 and 14 weeks. If the ultrasound date and your menstrual date agree within three days (seven days if the ultrasound is after 14 weeks), the dating is considered reliable. If they disagree, your provider uses the ultrasound date because it is more accurate early in pregnancy.
Accurate dating matters most for the quad screen because the four markers change rapidly during weeks 15 through 22. If your dating is uncertain or disputed, your provider might recommend waiting until the structural ultrasound at 18 to 22 weeks and using that ultrasound's measurements to finalize your date before interpreting the blood test results.
Most pregnancies have screening performed at 16 to 18 weeks. This window gives the clearest signal from the blood markers and still allows time for follow-up ultrasound and genetic counseling if results are abnormal. Some clinics offer sequential screening, in which they perform a first-trimester test (between 11 and 14 weeks) and then the second-trimester quad screen, using both results together for a more accurate risk assessment. Ask your provider which approach your clinic offers.
What the Quad Screen Blood Test Measures
[AFP for neural tube defects, F4] [Four blood markers, F1] Alpha-fetoprotein (AFP) is produced by the fetus and crosses into your bloodstream. Elevated AFP levels suggest neural tube defects such as spina bifida; lower-than-expected levels are associated with chromosomal abnormalities like Down syndrome. AFP levels rise progressively through pregnancy, which is why gestational age is so important.
Human chorionic gonadotropin (hCG) is the hormone your body produces in early pregnancy and which pregnancy tests detect. In the second trimester, hCG levels that are higher than expected increase risk for Down syndrome and trisomy 18, while lower levels suggest neural tube defects. The relationship between hCG and chromosomal risk is opposite that of AFP—high hCG is risky for chromosomal conditions, while high AFP flags structural concerns.
Unconjugated estriol (uE3) is an estrogen produced by both your placenta and the fetus. Lower-than-expected uE3 levels are associated with Down syndrome and trisomy 18. Because three of the four markers point in similar directions for chromosomal risk (high hCG, low AFP, low uE3), the combination is more reliable than any single marker alone. Inhibin-A, the fourth marker, is produced by your placenta.
Elevated inhibin-A levels increase the likelihood of Down syndrome. This marker was added to screening in the 1990s because it improved detection rates for Down syndrome specifically; a triple screen without inhibin-A detects only about 69% of cases, while the quad screen detects 81–83%. Your lab results will show each marker's measured value, your gestational age, and your calculated risk—usually expressed as a ratio (e.g., 1 in 250) or as a percentage. The results also show the threshold the lab uses to call a result "high risk" or "low risk." This threshold can vary between labs, so ask your provider how your specific results compare to the lab's definition of normal.
The Anatomy Ultrasound at 18-22 Weeks
[Structural ultrasound 18-22 weeks recommended, success rates better at 20+ weeks, F3] The anatomy ultrasound is also called the level-two ultrasound or the fetal survey. Unlike an early-pregnancy ultrasound, which confirms viability and dating, the anatomy scan deliberately examines every fetal structure: the brain, heart, lungs, stomach, kidneys, limbs, spine, and umbilical cord. This scan takes 30 to 45 minutes and is the most detailed imaging most pregnancies will have.
The sonographer looks for structural abnormalities—malformations, underdevelopment, or unusual size—but also looks for "soft markers," which are anatomic features that are not abnormal by themselves but are slightly more common in babies with chromosomal abnormalities. Soft markers might include a bright spot in the heart, shortened femur length, or enlarged kidney size. A soft marker does not mean your baby has a chromosomal condition; it simply means your risk may shift slightly.
Ultrasound detection of structural problems improves significantly after 20 weeks of gestation. A scan at 18 weeks can miss abnormalities that are obvious at 20 weeks, and a scan at 22 weeks is more thorough still. For this reason, many providers recommend the anatomy ultrasound at 20 to 22 weeks rather than 18 weeks, though the exact timing is individualized.
If your anatomy ultrasound finds a potential abnormality, a follow-up ultrasound with maternal-fetal medicine expertise may be recommended. The anatomy ultrasound refines your screening risk. If the ultrasound is normal, your risk of chromosomal abnormalities decreases. If subtle findings are present, your risk may increase slightly, and your provider may recommend additional counseling or testing. If the ultrasound shows a structural abnormality, genetic counseling becomes even more important because some structural problems are associated with specific chromosomal conditions.
Understanding Detection Rates and False Positives
[Quad screen 81-83% detection, 5% false-positive rate, F2] [False-positive 5-10%, negative doesn't eliminate risk, F6] Detection rate means the percentage of pregnancies with a condition that the test successfully identifies. The quad screen detects 81–83% of Down syndrome cases—which means it misses 17–19% of cases. Those missed cases will not show an abnormal screening result, so parents will not know beforehand that their baby has Down syndrome.
A negative screening result does not mean your baby definitely does not have Down syndrome; it means your risk is lower than the screening threshold. The false-positive rate is the percentage of normal pregnancies that produce an abnormal screening result. For the quad screen, this is about 5%. If your screening is positive (high risk), there is roughly a 95% chance you received that result because your markers naturally vary that way, not because your baby has a chromosomal condition.
This is why screening is not diagnosis: most positive results turn out to be false alarms. Maternal age strongly affects both detection and false-positive rates. Older maternal age is associated with higher chromosomal risk, so a 45-year-old's risk of Down syndrome is much higher than a 25-year-old's. Because older mothers start with higher baseline risk, a positive screening result is more likely to represent true increased risk in that group.
In younger mothers, chromosomal risk is already low, so a positive result is more likely to be a false positive. Your individual detection rate depends on your age, your specific marker values, your ultrasound findings, and your dating accuracy. A provider or genetic counselor can calculate your personalized risk based on these factors. A risk of 1 in 100 is considered high risk by most labs, while 1 in 250 to 1 in 1,000 is considered low risk.
These are guidelines, not hard rules—your clinician will discuss what the numbers mean for you. Accuracy also depends on accurate dating. If your gestational age is off by two weeks, your risk calculation is meaningless. This is why your provider will confirm your dates before offering interpretation of screening results, and why the structural ultrasound's measurement-based dating is used to finalize your age if the blood test date is uncertain.
What a Positive Result Means (and Does Not Mean)
[Screening not diagnostic, positive needs counseling and amniocentesis/CVS discussion, F5] A positive screening result means your risk for a chromosomal abnormality has increased compared to your age and population average. It does not mean your baby definitely has the condition. It does mean you need to meet with a genetic counselor to discuss your individual circumstances, review the results in detail, understand what they do and do not tell you, and explore your next options.
After a positive quad screen, your provider will typically recommend a follow-up ultrasound with maternal-fetal medicine expertise, sometimes called a targeted ultrasound or specialized ultrasound. This ultrasound looks more carefully for structural features and soft markers associated with chromosomal abnormalities. A normal targeted ultrasound can lower your risk significantly; an ultrasound with concerning findings can raise it.
If you want a definitive answer, the next step is diagnostic testing: amniocentesis or chorionic villus sampling (CVS). Amniocentesis involves inserting a thin needle through the uterus to collect amniotic fluid, which contains fetal cells; CVS involves a needle through the cervix or abdomen to collect placental tissue. Both tests carry a small risk of miscarriage—less than 0.1–0.2% for amniocentesis and slightly higher for CVS—but they directly examine fetal genetic material and can definitively diagnose or rule out Down syndrome, trisomy 18, and trisomy 13.
You may also choose not to pursue diagnostic testing and instead carry the pregnancy forward knowing your increased risk but without a confirmed diagnosis. This decision is entirely yours, and your genetic counselor can help you think through what information matters to you and how you would use a diagnosis if you had one. Some families want to prepare for a possible diagnosis; others prefer not to know unless there are medical decisions to make.
A positive screening can feel frightening or uncertain. Many positive results will ultimately be false alarms—your ultrasound will be normal and your baby will be born without Down syndrome or other chromosomal conditions. Genetic counseling and a follow-up ultrasound provide clarity. Do not hesitate to ask your counselor to repeat information or to bring a partner or support person to appointments.
Screening Versus Diagnosis: What Comes Next
[Screening not diagnostic; diagnostic options are amniocentesis/CVS with small miscarriage risk, F5] The word "screening" is precise: these tests screen for risk. They do not diagnose a condition. Diagnosis requires examining fetal genetic material directly, which is why diagnostic testing—amniocentesis or CVS—exists as a separate step that only some people pursue. Many pregnancies never need diagnostic testing.
If your screening result is low risk, your baby's risk for a chromosomal abnormality has dropped, and no further testing is needed. If your screening result is high risk but your follow-up ultrasound is normal, your risk drops again significantly, and some families stop there. Others want absolute certainty and choose a diagnostic test even with reassuring ultrasound findings.
Amniocentesis is performed between 15 and 20 weeks of pregnancy. The procedure takes several minutes; you lie back while the doctor inserts a needle through your abdomen and uterus into the amniotic sac, aspirates about 15 to 20 milliliters of amniotic fluid, and withdraws the needle. The fluid contains fetal cells, which are cultured and analyzed.
Results typically return within 7 to 14 days for conventional analysis (full karyotype) or within a few days for rapid testing (looking at chromosome 21, 18, and 13 only). Chorionic villus sampling (CVS) is performed between 10 and 13 weeks, earlier than amniocentesis. It can be done through the cervix (transcervical) or through the abdomen (transabdominal).
Like amniocentesis, CVS carries a small miscarriage risk, slightly higher than amniocentesis, and results take similar time to return. Both diagnostic tests require informed consent and genetic counseling beforehand. Both carry the risk of miscarriage, infection, or other complications. Neither test is necessary unless you want diagnostic information; many pregnancies proceed without it. Your genetic counselor will discuss your options thoroughly and help you decide what is right for you.
Why Accurate Gestational Age Matters More Than You'd Think
[Accurate dating critical, marker levels vary by week, F7] Gestational age is the single most important variable in interpreting second trimester screening results. Every marker—AFP, hCG, uE3, inhibin-A—changes week by week. A measurement that is normal for 16 weeks is abnormal for 14 weeks and different again for 18 weeks. If your age is wrong, your interpretation is wrong.
Your menstrual history gives a rough estimate, but ultrasound is more accurate, especially early in pregnancy. An ultrasound between 8 and 14 weeks can date a pregnancy to within 3 days; an ultrasound after 20 weeks is accurate to only plus or minus 3 to 5 weeks. This is why most providers confirm dating in the first trimester and use that date throughout pregnancy.
If your menstrual date and ultrasound date disagree by more than the expected margin of error, your provider uses the ultrasound date. For example, if your last menstrual period says you're 16 weeks pregnant but the ultrasound measurements suggest 18 weeks, the ultrasound date is used because it's more reliable. The difference of two weeks would change every screening marker interpretation.
When you go for your quad screen blood draw, make sure your provider knows which gestational age to use for interpretation. Ask the lab to confirm your age on the report before results are released. If there is any uncertainty about dating when results come back, ask your provider to repeat the blood test at a later date when dating can be confirmed by the anatomy ultrasound, or to calculate your risk using the ultrasound-confirmed dates.
Conversely, if you had an early ultrasound that perfectly confirmed your menstrual dates, mention that to the lab. Some labs will adjust their marker interpretation slightly if they know your date is especially reliable. Accurate dating ensures your results are meaningful.
Screening Is Offered to All Pregnant People, Regardless of Age
All pregnant patients should be offered screening and genetic counseling, F8] Genetic screening recommendations have changed significantly over the past decade. Older guidelines recommended offering invasive prenatal testing primarily to women age 35 and older, often called "advanced maternal age." Current guidelines from [the American College of Obstetricians and Gynecologists now recommend that all pregnant patients, regardless of age, be offered prenatal screening and genetic counseling.
This change reflects the reality that chromosomal conditions occur across all maternal ages. While Down syndrome is more common in pregnancies of older mothers—about 1 in 1,500 at age 20 versus 1 in 100 at age 45—the majority of babies with Down syndrome are born to women under age 35 simply because younger women have more pregnancies overall.
Age alone does not determine your need for screening or your actual risk. Some younger mothers opt out of screening because they feel their age-related risk is already low. Others, regardless of age, want information and choose screening. Some older mothers feel they don't need screening because they have already decided to continue any pregnancy regardless of results.
Others want to prepare or to confirm their due date. Your age is only one input into your decision, not the decision itself. Your provider should offer you screening options, explain them, answer your questions, and respect your choice whether to proceed. If you decline screening, that decision should be documented in your medical record so there's no confusion about whether you were offered it.
If you accept screening, you should receive educational materials and the chance to ask questions before the blood draw. Genetic counselors can help you decide whether screening fits your values and goals. Many insurances cover genetic counseling before screening even if you initially say no; ask your provider whether counseling is available to you at no cost.
Questions to Ask Your Care Provider Before and After Screening
[Screening combined with counseling, F8] Before you decide whether to have screening, ask your provider: "What will you do with these results? What are my options if the screening is abnormal? How long will results take? Do I need to understand anything else to make this decision?" These questions help you clarify what information matters to you and why. When you have your screening blood drawn, confirm with the lab tech that your gestational age is entered correctly.
Ask the lab how long results will take and how you'll receive them. Ensure your provider's office will call you with results rather than having you look them up online without context, especially if results are abnormal. When results return, ask your provider to explain what your specific numbers mean. Ask whether your results are considered high risk or low risk according to their lab's threshold.
Ask what your calculated risk ratio means—a 1 in 250 risk, for example—and whether that matches your personal comfort level. Ask whether follow-up ultrasound is recommended. If your result is positive or concerning, ask for a referral to a genetic counselor before making any decisions about further testing. Genetic counselors specialize in helping you understand what tests mean, what your options are, and what diagnostic testing involves.
Ask the counselor to explain what amniocentesis or CVS would tell you and whether either test fits your circumstances. Ask your provider what soft markers or findings on the anatomy ultrasound would concern them and why. Ask whether a normal anatomy ultrasound after an abnormal screening result means your risk has dropped, and by how much.
Ask what follow-up or monitoring, if any, would be recommended during the rest of your pregnancy. There are no stupid questions in this conversation. Screening results can feel overwhelming. Your provider and genetic counselor are there to help you understand, not to judge your choices.
- —
Frequently Asked Questions
Is second trimester screening the same as the anatomy ultrasound?
No. Second trimester screening includes two separate tests: a blood test (quad screen) done between 15 and 22 weeks, and a structural ultrasound typically done at 18 to 22 weeks. The blood test measures four markers; the ultrasound visualizes fetal structures. Together they estimate your risk, but neither confirms a diagnosis.
What if my quad screen is positive—does that mean my baby has Down syndrome?
No. A positive quad screen means your risk is higher than average for your age, but about 95% of positive results turn out to be false alarms—the baby does not have Down syndrome. You would need diagnostic testing (amniocentesis or CVS) to confirm or rule out a chromosomal condition.
How accurate is the quad screen?
The quad screen detects 81–83% of Down syndrome cases, according to research. That means it misses 17–19% of cases. A negative result is reassuring but not a guarantee; a positive result usually needs follow-up ultrasound or diagnostic testing.
Does my age affect whether I should get screening?
Age affects your baseline chromosomal risk and how to interpret results, but all pregnant patients should be offered screening, regardless of age. Chromosomal conditions occur across all maternal ages. Ask your provider whether screening fits your goals.
What is the difference between screening and diagnostic testing?
Screening estimates your risk but does not diagnose. Diagnostic testing (amniocentesis or CVS) examines fetal genetic material directly and can definitively confirm or rule out chromosomal conditions. Diagnostic tests carry a small miscarriage risk, so they are offered only to those who want definitive information.
Can I refuse screening?
Yes. Screening should be offered to all pregnant patients, but it is optional. You can decline screening, accept it after thinking about it, or proceed without genetic counseling if you prefer. Your choice should be documented in your medical record.
